Progyny (NASDAQ:PGNY) Releases Quarterly Earnings Results, Misses Estimates By $0.28 EPS

Progyny (NASDAQ:PGNY) issued its quarterly earnings data on Thursday. The company reported $0.08 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.36 by ($0.28), Zacks reports. Progyny had a net margin of 5.03% and a return on equity of 11.36%. Progyny updated its Q1 2025 guidance to 0.440-0.470 EPS and its FY 2025 guidance to 1.520-1.620 EPS.

Progyny Price Performance

Progyny stock traded down $0.12 during midday trading on Thursday, hitting $22.88. The company’s stock had a trading volume of 2,436,975 shares, compared to its average volume of 1,794,328. The company has a 50-day moving average price of $20.34 and a two-hundred day moving average price of $18.65. Progyny has a 1-year low of $13.39 and a 1-year high of $38.98. The company has a market cap of $1.95 billion, a price-to-earnings ratio of 39.45, a PEG ratio of 2.39 and a beta of 1.34.

Analysts Set New Price Targets

PGNY has been the topic of a number of research analyst reports. Barclays dropped their price objective on shares of Progyny from $30.00 to $17.00 and set an “overweight” rating on the stock in a report on Thursday, November 14th. Bank of America lifted their price target on shares of Progyny from $21.00 to $25.00 and gave the company a “buy” rating in a research note on Tuesday, February 11th. Truist Financial reissued a “hold” rating and set a $19.00 price target (down from $26.00) on shares of Progyny in a research report on Wednesday, November 13th. JPMorgan Chase & Co. boosted their price target on Progyny from $17.00 to $23.00 and gave the stock a “neutral” rating in a research report on Tuesday, January 28th. Finally, Canaccord Genuity Group lowered their target price on shares of Progyny from $18.00 to $17.00 and set a “hold” rating on the stock in a report on Wednesday, November 13th. Nine analysts have rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $25.83.

Insider Transactions at Progyny

In related news, Chairman David J. Schlanger bought 150,000 shares of the business’s stock in a transaction dated Thursday, December 26th. The stock was purchased at an average cost of $14.68 per share, for a total transaction of $2,202,000.00. Following the transaction, the chairman now owns 228,269 shares in the company, valued at $3,350,988.92. The trade was a 191.65 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Peter Anevski purchased 209,500 shares of the company’s stock in a transaction that occurred on Monday, December 23rd. The stock was bought at an average cost of $14.48 per share, with a total value of $3,033,560.00. Following the purchase, the chief executive officer now owns 441,463 shares of the company’s stock, valued at $6,392,384.24. This represents a 90.32 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders own 12.30% of the company’s stock.

About Progyny

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.